You are here

Colorado’s Attorney General Sues Purdue Pharma

Says Company’s OxyContin Had “Significant Role” in Opioid Epidemic

In the aftermath of hundreds of lawsuits over the years against pharmaceutical giant Purdue Pharma, Colorado’s attorney general is now suing the OxyContin creator for what it calls its “significant role in causing the opioid epidemic.”

The lawsuit claims that Purdue Pharma L.P. and Purdue Pharma Inc. misled doctors and patients in Colorado about the potential for addiction with prescription opioids and continued to push the drugs. The lawsuit further states that Purdue Pharma “downplayed the risk of addiction associated with opioids,” “exaggerated the benefits” and “advised health care professionals that they were violating their Hippocratic Oath and failing their patients unless they treated pain symptoms with opioids,” according to the statement from the Colorado attorney general’s office.

Purdue Pharma has vigorously denied the accusations in a statement to The Washington Post, saying that although it shares “the state’s concern about the opioid crisis,” it did not mislead health care providers about prescription opioids.

In 2016, there were more than 63,000 drug overdose deaths in the United States, and more than 66 percent of them were attributed to opioids, according to the most recent data from the Centers for Disease Control and Prevention.

Source: Washingtonpost.com, September 8, 2018

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function